China's Lab Monkey Prices Surge to COVID-19 Peak Amidst Drug R&D Boom
The cost of laboratory monkeys in China has reached unprecedented levels, mirroring prices seen during the COVID-19 pandemic, due to a significant increase in demand from the nation's burgeoning drug research and development sector. This surge in prices, which began after Chinese New Year, is now forcing some researchers to pause their critical studies. Guo Xiangyu, a scientist at Jinan University in Guangzhou specializing in non-human primate models for brain diseases, confirmed the steady price increase. Currently, suppliers are quoting approximately 180,000 yuan (US$27,000) per animal. The high cost is creating substantial financial barriers for research institutions, potentially slowing down the pace of scientific discovery and the development of new treatments.
The escalating cost of laboratory primates in China highlights a critical bottleneck in the nation's rapidly expanding biopharmaceutical research landscape. This price surge, driven by increased demand for drug R&D, reveals potential systemic vulnerabilities in the supply chain for essential research materials. As costs rise, research institutions face difficult decisions regarding study continuation, potentially impacting innovation timelines. This situation underscores the need for strategic planning and investment in sustainable primate breeding programs and alternative research models to ensure the continued growth and competitiveness of China's life sciences sector in the coming decade.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.